Concerning reports about potential mortality rates caused by paclitaxel-coated devices have been raised by the FDA. Read more


A combination of drugs has offered promising results in an early clinical trial, where it has shrunk tumours in ovarian and lung cancer patients and prevented tumour growth for nearly six months. Read more


Oraxol is an oral form of the approved drug paclitaxel, with HM30181, a highly potent and selective, P-glycoprotein inhibitor of the gastro-intestinal tract. Read more

Novasep has announced that the FDA successfully audited two of its European custom manufacturing sites in Le Mans, France and Leverkusen, Germany. FDA investigators audited the two facilities in June and July 2013. Read more